1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. China Medical System Holdings Limited
  6. Summary
    867   KYG211081248

CHINA MEDICAL SYSTEM HOLDINGS LIMITED

(867)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Hong Kong Stock Exchange
05/12/2022 05/13/2022 05/16/2022 05/17/2022 05/18/2022 Date
10.66(c) 11.06(c) 10.96(c) 11.04(c) 11.2(c) Last
1 989 100 2 265 328 2 793 640 1 444 000 2 203 088 Volume
-0.37% +3.75% -0.90% +0.73% +1.45% Change
More quotes
Estimated financial data (e)
Sales 2022 9 458 M 1 400 M 1 400 M
Net income 2022 3 332 M 493 M 493 M
Net cash position 2022 3 109 M 460 M 460 M
P/E ratio 2022 7,19x
Yield 2022 5,67%
Sales 2023 10 504 M 1 555 M 1 555 M
Net income 2023 3 624 M 537 M 537 M
Net cash position 2023 4 413 M 653 M 653 M
P/E ratio 2023 6,60x
Yield 2023 6,21%
Capitalization 23 636 M 3 500 M 3 500 M
EV / Sales 2022 2,17x
EV / Sales 2023 1,83x
Nbr of Employees 5 292
Free-Float 50,6%
More Financials
Company
China Medical System Holdings Limited is a Hong Kong-based investment holding company principally engaged in the manufacture, marketing, promotion and sales of pharmaceutical products. Its main products under direct network include Deanxit, Ursofalk, XinHuoSu, Salofalk, Bioflor and Augentropfen Stulln Mono Eye-drops, among others. Its products under the agency promotion network include ShaDuoLiKa, YiNuoShu and... 
Sector
Pharmaceuticals
Calendar
08/22Earnings Release
More about the company
Ratings of China Medical System Holdings Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about CHINA MEDICAL SYSTEM HOLDINGS LIMITED
04/26CHINA MEDICAL SYSTEM HOLDINGS LIMITE : Ex-dividend day for final dividend
FA
04/22China Medical System Holdings Limited Approves Final Dividend for the Year Ended Decemb..
CI
03/15China Medical System Posts Higher Earnings in 2021; Shares Jump 5%
MT
03/15China Medical System Holdings Limited Recommends Final Dividend for the Year Ended 31 D..
CI
01/13Gelesis Holdings, Inc. announced that it has received $97.44217 million in funding from..
CI
2021China Medical System Secures Rights to South Korean Medical Aesthetic Firm's Embedding ..
MT
2021CHINA MEDICAL SYSTEM : Voluntary and Business Update Announcement Achieving Collaboration ..
PU
2021Chinese Regulators Accept China Medical System's New Drug Application for Psoriasis Tre..
MT
2021China Medical System Holdings Limited Announces New Drug Application of Methotrexate In..
CI
2021China Medical System Arm Buys Chinese Medical Aesthetic Specialty Firm; Shares Rally 12..
MT
2021CHINA MEDICAL SYSTEM : New Drug Application for Psoriasis Treatment Accepted by Regulators
MT
2021China Medical System Holdings Limited Announces Change of Independent Non-Executive Dir..
CI
2021China Medical System Holdings Limited Establishes A New Programme with XF-73 Targeting ..
CI
2021China Medical System Holdings Limited Joins BaseLaunch as Latest Partner
CI
2021DTrade Labs Inc. announced that it has received $22.8 million in funding from Alameda R..
CI
More news
News in other languages on CHINA MEDICAL SYSTEM HOLDINGS LIMITED
04/22China Medical System Holdings Limited approuve le dividende final pour l'année se termi..
03/15China Medical System affiche des bénéfices plus élevés en 2021 ; les actions bondissent..
03/15China Medical System Holdings Limited recommande un dividende final pour l'exercice clo..
01/04HONG KONG : Lam rejette l'idée d'une "extinction" de la liberté de la presse
01/03Hong Kong-Lam rejette l'idée d'une "extinction" de la liberté de la presse
More news
Chart CHINA MEDICAL SYSTEM HOLDINGS LIMITED
Duration : Period :
China Medical System Holdings Limited Technical Analysis Chart | 867 | KYG211081248 | MarketScreener
Technical analysis trends CHINA MEDICAL SYSTEM HOLDINGS LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 9,64 CNY
Average target price 16,03 CNY
Spread / Average Target 66,3%
EPS Revisions
Managers and Directors
Kong Lam Chairman, President & Chief Executive Officer
Yan Ling Chen Chief Financial Officer, Executive Director & VP
Wai Ming Wong Chief Technical Officer
Hong Bing Chen Chief Operating Officer, Executive Director & VP
Chong Shun Leung Independent Non-Executive Director